Aaron Mishel

Chief Financial Officer

Aaron Mishel joined Escient Pharmaceuticals in August 2022 as Chief Financial Officer. He brings to the company over twenty years of broad experience in the life sciences and financial services sectors. Prior to Escient, he served as CFO or Head of Finance for several venture-backed private healthcare companies: GenEdit (2021-2022), Magnetic Insight (2020-2021), and Modis Therapeutics (2018-2020), where he led financial strategy, fundraising, investor relations, financial planning, accounting, and administrative functions. At Modis Tx, he was a member of the executive team that led the company’s sale to Zogenix for $400M+ in late 2019. Previously, he worked in finance and business development at BioMarin Pharmaceutical from 2014-2018, most recently as a Director of Business & Corporate Development, leading the evaluation and execution of licensing and acquisition transactions. Before this he spent six years in Equity Research at two investment banks – Deutsche Bank and Thomas Weisel Partners – covering the specialty pharmaceuticals industry. Previously, he worked in Finance at CV Therapeutics (acquired by Gilead), leading the FP&A group, responsible for corporate-wide budgeting and financial planning. He began his career as a product development engineer in the medical device field, designing devices for minimally invasive cardiovascular procedures. He holds a B.S. in Biomedical Engineering and a B.A. in Economics from Brown University and an MBA from the Stanford Graduate School of Business.